X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

PCI Announces Further Investment in Fully Contained Xcelodose® 600S Technology Delivering Excellence in Clinical Services

Yuvraj_pawp by Yuvraj_pawp
1st November 2017
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

PCI Pharma Services is excited to announce further market leading investment in fully contained Xcelodose® 600S technology at our center of excellence for contained manufacturing; Tredegar, UK.

This investment delivers another important capability for the award-winning facility in the development and manufacturing of highly potent molecules. The pharmaceutical landscape continues to evolve with more and more products in development being deemed potent. As the biological activity and specificity of Active Pharmaceutical Ingredients (API) increases, dosage strengths are decreasing which has led to molecules becoming more potent in nature.

The pharmaceutical industry’s on-going demand to shorten drug development times, saving both time and money, is driving technological advances. The traditional product development route of formulating a solid dosage form for Phase I studies typically involves a range of complex activities including analytical method development, prototype development, short-term stability, process/formulation refinement, validation and finally clinical manufacture.

Manufacturing drug in capsule (DIC) is a way to significantly reduce both the time and financial investment at the early stage of the drug development process, providing faster delivery for first-time-in-man. This approach minimizes the use of costly API, and reduces the amount of formulation and analytical development necessary to support an Investigation New Drug (IND) application or Investigational Medicinal Product Dossier (IMPD).

Xcelodose® technology delivers this drug in capsule process, removing the need for initial formulation/analytical development and the associated stability testing, enabling PCI to achieve faster times to first-in-man studies on behalf of its clients. In 2010 PCI invested in Xcelodose® 120S technology, a semi-automated system to provide early stage clinical supplies. This additional investment in fully automated Xcelodose® 600S technology delivers a programmable system providing exceptional levels of accuracy and precision.

This state-of-the-art technology has the capability to fill amounts as low as 100 micrograms at speeds of more than 600 capsules per hour. Waste of API is minimized and batch documentation allows traceability of individual capsules that meet GMP requirements. The Xcelodose® 600S technology is further enhanced by a PCI-designed, custom-built XceloprotectTM containment system providing an early stage development solution for the management of highly potent molecules. The high levels of containment provide Occupational Exposure Limits (OEL) as low as 0.1µg/m3 over an eight-hour time weighted average, meeting Safebridge 3 and 4 categorization, preventing operator exposure and adhering to the very latest regulatory requirements.

PCI is a trusted partner for the management of clinical programs, from the initial early stage development and manufacturing using technologies such as Xcelodose®, through clinical trial supply services including packaging, labeling, storage and distribution. Most recently PCI launched its FastTrackTM service offering a demand-led approach to the delivery of secondary packaging, labeling, release and distribution of clinical supplies based on patient and site requirements. This service provides compliant clinical supplies for time-critical studies and, depending on availability of materials, delivers projects in less than ten working days.

Commenting on the new technology, David O’Connell, Director of Pharmaceutical Development at PCI said: “This is a very exciting time as we add this important technology to our capabilities. Being able to offer this service for early stage development programs will deliver both time and cost efficiencies for our customers.”

O’Connell continued: “As molecules increase in potency, API is often very expensive and in short supply. By being able to fill drug directly into capsules and accelerate first-time-in-man studies, customers will be able to assess very quickly whether the project will progress to the next stage or ‘fail and fail fast’ – thereby minimizing costs, and enabling informed decisions to be made.“

Previous Post

Lao PDR to Improve Health and Nutrition for Mothers and Children, with World Bank Support

Next Post

Servier Germany to co-promote Novartis’ blockbuster Entresto®

Related Posts

Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Next Post

Servier Germany to co-promote Novartis’ blockbuster Entresto®

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In